Table 2.
Primary and secondary outcomes at day 21 in patients with coronavirus disease 2019 assigned to hydroxychloroquine (treatment group) or no hydroxychloroquine (control group)
| Outcomes | No of events | Ratio (95% CI) | IPTW ratio (95% CI)* | |
|---|---|---|---|---|
| Treatment group (n=84) | Control group (n=89) | |||
| Survival without transfer to intensive care unit | 17 | 22 | HR 0.8 (0.4 to 1.5) | wHR 0.9 (0.4 to 2.1) |
| Overall survival (No of deaths) | 9 | 8 | HR 1.2 (0.5 to 3.0) | wHR 1.2 (0.4 to 3.3) |
| Survival without acute respiratory distress syndrome | 25 | 23 | HR 1.2 (0.7 to 2.2) | wHR 1.3 (0.7 to 2.6) |
| Oxygen weaning | 66 | 66 | RR 1.1 (0.9 to 1.3) | wRR 1.1 (0.9 to 1.3) |
| Discharge from hospital to home or rehabilitation | 67 | 71 | RR 1.0 (0.9 to 1.2) | wRR 0.9 (0.8 to 1.2) |
HR=hazard ratio; IPTW=inverse probability of treatment weighting; RR=relative risk; wHR=weighted hazard ratio; wRR=weighted relative risk.
*
Weighted hazard ratios, weighted relative risks, and 95% confidence intervals were obtained by inverse probability treatment weighting. A multivariable logistic regression model was constructed to estimate each patient’s probability of receiving hydroxychloroquine given their baseline covariates (that is, the propensity score: variables in model included age, sex, and comorbidities)